SOURCE: Dako A/S

June 01, 2007 03:26 ET

EQT's acquisition of Dako has been completed

GLOSTRUP, DENMARK--(Marketwire - June 1, 2007) -


EQT V Limited ("EQT")'s acquisition of Dako Denmark A/S, the worlds leading supplier of cancer diagnostics, closed on 31 May 2007.

Private equity fund, EQT has acquired Dako Denmark A/S for an enterprise value of DKK 7.25 billion, as announced on 28 February 2007. The transaction has been approved by the relevant competition authorities and by the shareholders of Dako.

As new owners, EQT's intention is to support Dako's management in a more aggressive growth strategy and further develop the company within the cancer diagnostics field. The strategy for Dako is to focus on the entire workflow of the pathology labs to improve quality, safety and cost efficiency by connecting reagents, instruments and software for the benefit of the doctors, the labs and especially the patients waiting for diagnoses.

New Board of Directors

EQT has appointed a new Board of Directors to support Dako to continue to pioneer the development of cancer diagnostics. Chairman of the new Dako Board will be Mats Fischier.

"Dako is a very attractive company due to its brand, its antibody expertise and its strategy to embrace the full pathology workflow for developing more efficient and safer cancer diagnostics. The company has a huge potential that has not been fully exploited. We will be looking at ways to accelerate Dako's growth by adding to the strategy laid out by Dako's corporate management team. As new chairman of Dako's board, I look forward to working with the management team to explore Dako's opportunities in the cancer diagnostics field further", says Mats Fischier.

Mats Fischier, B.Sc., has gained extensive industrial experience while serving in several key positions. Today, Mats Fischier is chairman of Gambro BCT and Gyros AB and ordinary board member of Atos Medical and Mölnlycke Healthcare. Previously he has held positions as chairman of Phadia AB, CEO and later chairman of Perbio Science, divisional president in Perstorp AB and Nobel Industries as well as CEO of Medipharm AB.

In addition to Mats Fischier, the new Dako Board currently includes Søren Mellstig, Ole Andersen and Morten Hummelmose (see CVs below). It is the intention to further strengthen the board with two additional members with relevant industry experience.

Ole Andersen, Partner EQT Partners A/S
MSc in economics, state authorized public accountant.
Former occupation:
1983-1997: Arthur Andersen & Co., Skandinavisk Holding,
Scandinavian Capital Partner and Alfred Berg
1997-2000: Head of the Copenhagen Branch of Enskilda Securites
2000-2003: Global Head of Corporate Finance Enskilda Securites
Member of the boards of ISS  A/S, Contex Holding A/S, Aleris AB,
and BTX Group A/S

Morten Hummelmose, Director EQT Partners A/S
M.Sc. in Economics from the University  of Copenhagen and a M.Sc.
in Finance from the University of London
Former occupation:
1995-1998: Aros Securities (now Nordea) in Copenhagen
1998-2001: Goldman Sachs International in London
2001-2006: Enskilda Securities in Copenhagen
Member of the board of Leybold Optics GmbH

Søren Mellstig
Former CEO of Gambro AB. Chairman of the Board in Aleris AB and
ordinary board member in Munters AB, Ferrosan A/S and PaloDEx Oy.


Media contacts:
Dako Denmark A/S
Anne Thommesen, Corporate Communications, +45 40 63 95 93

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information